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ABSTRACT
Background
The anticipated scale-up of antiretroviral therapy (ART) in high-prevalence, resource-
constrained settings requires operational research to guide policy on the design of treatment
programmes. Mathematical models can explore the potential impacts of various treatment
strategies, including timing of treatment initiation and provision of laboratory monitoring
facilities, to complement evidence from pilot programmes.
Methods and Findings
A deterministic model of HIV transmission incorporating ART and stratifying infection
progression into stages was constructed. The impact of ART was evaluated for various scenarios
and treatment strategies, with different levels of coverage, patient eligibility, and other
parameter values. These strategies included the provision of laboratory facilities that perform
CD4 counts and viral load testing, and the timing of the stage of infection at which treatment is
initiated. In our analysis, unlimited ART provision initiated at late-stage infection (AIDS)
increased prevalence of HIV infection. The effect of additionally treating pre-AIDS patients
depended on the behaviour change of treated patients. Different coverage levels for ART do
not affect benefits such as life-years gained per person-year of treatment and have minimal
effect on infections averted when treating AIDS patients only. Scaling up treatment of pre-AIDS
patients resulted in more infections being averted per person-year of treatment, but the
absolute number of infections averted remained small. As coverage increased in the models,
the emergence and risk of spread of drug resistance increased. Withdrawal of failing treatment
(clinical resurgence of symptoms), immunologic (CD4 count decline), or virologic failure (viral
rebound) increased the number of infected individuals who could benefit from ART, but
effectiveness per person is compromised. Only withdrawal at a very early stage of treatment
failure, soon after viral rebound, would have a substantial impact on emergence of drug
resistance.
Conclusions
Our analysis found that ART cannot be seen as a direct transmission prevention measure,
regardless of the degree of coverage. Counselling of patients to promote safe sexual practices
is essential and must aim to effect long-term change. The chief aims of an ART programme,
such as maximised number of patients treated or optimised treatment per patient, will
determine which treatment strategy is most effective.
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Antiretroviral therapy (ART) has greatly reduced HIV/
AIDS-related mortality and morbidity in industrialised
countries [1]. Because it reduces a patient’s viral load, it is
also believed to reduce infectiousness [2], and so has been
suggested as a prevention tool in its own right, as well as a
treatment [3]. As prevention efforts in resource-poor settings
have not always met with success, especially in high-
prevalence areas of Africa [4,5], this could be an important
additional goal of the accelerated roll-out of ART across the
continent. In order to maximise the beneﬁt of ART to
patients and their communities, its impact on HIV epidemics
should be evaluated, and different approaches to ART
delivery should be investigated.
The effect that ART will have on transmission will rely not
only on its effect on life expectancy, infectiousness, and
treatment failure rates, but also on the stage of infection at
which treatment is initiated, levels of coverage (which rely on
the availability of resources and identiﬁcation of patients
qualifying for ART), and the scale and stage of HIV epidemic
that the community is experiencing.
Previous mathematical models have predicted that ART
will have a striking effect on transmission when coverage is
high. Models based on the HIV epidemic among men who
have sex with men in San Francisco [6] and Australia [7] have
produced optimistic outcomes, provided that risk-taking
behaviour (e.g., sexual partner change rate) does not increase
substantially. However, it is unlikely that treatment of
patients in resource-poor settings will be at an early stage
of infection (i.e., before CD4 cell counts reach 200 cells/ml or
less); many are diagnosed only when their CD4 counts have
reached less than 50 cells/ml [8,9]. Models need to explore
more realistic patterns of ART use in such settings,
incorporating the problems of late presentation of HIV
infection, rationing of ﬁnite resources, limited health care
facilities, and inadequate nutrition.
Among the issues that need addressing are inclusion and
exclusion criteria for ART programmes, which may involve
tuberculosis status (and with that perhaps a proven record of
good adherence from a Directly Observed Therapy Short-
Course, or DOTS, programme) and infection stage. ART may
be targeted at patients with AIDS, those most in need and
closest to death, or it may also be used for those with ‘‘pre-
AIDS’’ (deﬁned as the disease state at which the virus escapes
immune system control, and CD4 counts decline, but no
AIDS-deﬁning conditions [ADCs] appear). Patients treated at
the pre-AIDS stage are likely to have a better prognosis than
those treated after they have developed full AIDS, because of
preserved immune function, and they are likely to avoid the
complications associated with immune reconstitution syn-
drome [10]. Given that data are limited on effectiveness of
ART programmes in resource-poor settings, further inves-
tigation of possible optimal approaches—to include cost-
effectiveness analyses—would be valuable before programme
roll-out [11].
Mukherjee et al. [12] believe that the implementation of
ART cannot wait until sufﬁcient infrastructure is in place,
and they discuss the problem of limited laboratory infra-
structure, suggesting that a stepwise progression as more
resources become available would be appropriate. They
recommend initially implementing an ART programme
based on clinical management (or at most total lymphocyte
count), with sequential addition of CD4 count testing, viral
load testing, and resistance testing. Our analysis investigated
the effect of sequential adoption of these laboratory facilities
on key outcome measures. The adoption of CD4 count testing
allows for the identiﬁcation of infected individuals who
present without an ADC, but are still at a relatively late stage
of infection, with a CD4 count in decline (pre-AIDS patients).
The adoption of viral load testing can assist with the
identiﬁcation of such individuals, but additionally can
identify treatment failure with viral rebound, which can
precede by a substantial period a further decline in CD4
count or a reappearance of opportunistic infections [13–15].
However, where funds for HIV/AIDS diagnosis and treatment
are limited, the expense of such facilities restricts the number
of patients being treated. Furthermore, these facilities allow
the identiﬁcation of individuals who are more likely (pre-
AIDS patients) and less likely (those failing therapy) to beneﬁt
from ART, leading to difﬁcult ethical considerations con-
cerning prioritisation.
In the current study, we explore many of these issues by
predicting and comparing through modelling the epidemio-
logical impacts of alternative strategies, and in the process
provide an illustration of the trade-offs involved.
Methods
Model and Assumptions
A compartmental deterministic mathematical model de-
scribing HIV transmission and ART use was constructed. The
basic structure of the model is illustrated in Figure 1 and
described in more detail in Protocol S1. The model tracks two
HIV strains, one resistant to ART and one sensitive. Each
compartment of infected individuals has a deﬁned infec-
tiousness determined by treatment status and viral resistance
type. Superinfection is incorporated only for individuals
undergoing successful treatment for an ART-sensitive strain,
where superinfection with an ART-resistant strain can occur.
It is assumed that treatment failure (deﬁned as viral rebound
or failure to achieve viral suppression) precedes resistance
evolution.
ART. We assumed a single, standard triple-combination
therapy regimen, with no second-line or salvage therapy
available for those who experience treatment failure. The
World Health Organisation guidelines for ART use in
resource-poor settings recommend at least one combination
salvage therapy option [8], which may be feasible and could
be investigated by extending this model. However, as this may
not be realistic in all regions, especially where access to ﬁrst-
line therapy must be rationed, we believe that the assumption
of one ART regimen only is an appropriate starting point.
HIV and AIDS. In the model, an ART-resistant strain is
resistant to the triple regimen rather than to individual drugs
within that regimen. It is assumed that there is no pre-
existing background level of resistance in the population
generated by ART drug use outside the modelled ART
programme.
The model was solved numerically using the Runge-Kutte 4
algorithm in Berkeley Madonna version 8.0.1, but pro-
grammed concurrently using C for validation.
The model was stratiﬁed into four distinct HIV infection
stages with different associated infectiousness: primary
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period is further divided into eight compartments, with an
average duration in each of one year, in order to approximate
the average time spent in this stage more accurately than by
using an exponential distribution.
Sexual behaviour and treatment outcomes. Sexual partner-
ships in this type of model have no duration—they form (and
implicitly end) instantaneously, accompanied by infection
transmission, if this has been determined to occur. The model
assumes that all partnerships are heterosexual. It does not
distinguish between the sexes, but includes four sexual
activity classes. A small proportion of the population (0.1%)
is in the highest activity class; 26%, 59%, and 15% make up
the respective lower-activity classes, with partner change
rates of 153, 13.6, 0.5 and 0.2 partners per year, respectively.
These form sexual activity groups 1 to 4, respectively. All
individuals progressing to AIDS move to the least-active
group because of their illness.
Patients starting ART spend an average of six months in an
‘‘initial’’ compartment. For AIDS patients in this ‘‘initial’’
period, the assumed effects of ART on sexual activity are not
yet imposed—they have not yet sufﬁciently recovered to
increase any risk-taking behaviour. For pre-AIDS patients,
with milder disease, an immediate decrease in sexual activity
(dropping to the next lowest sexual activity class) is assumed
to follow diagnosis and effective counselling. The incorpo-
ration of these compartments allows for different treatment
outcomes for AIDS and pre-AIDS patients initiating ART.
On leaving this ‘‘initial’’ phase, a fraction of patients are
assumed to drop out (due to tolerability problems) and return
to the ‘‘untreated’’ compartment at the same infection stage.
The fraction that drops out is higher for AIDS patients than
for pre-AIDS patients, because of immune reconstitution
syndrome. A substantial proportion of treated AIDS patients
die after leaving this stage, an assumption that reﬂects the
high mortality observed in the ﬁrst few months of treatment
for those at late-stage infection [16]. All other patients move
to ‘‘successfully treated’’ or ‘‘unsuccessfully treated’’ compart-
ments, from which point patients initiating ART at AIDS and
pre-AIDS have the same progression rates. A fraction (85%)
of AIDS patients increase sexual activity after initiation of
ART and move to the next higher sexual activity group. For
simplicity, this effect does not wane with time. These are the
baseline assumptions regarding changes in the risk-taking
behaviour of HIV-infected patients upon initiating ART.
Resurgence of clinical symptoms was modelled as pro-
gression through eight treatment stages without symptoms
before development of a new ADC upon entering the ninth
compartment, when all patients revert back to the lowest
sexual activity group. ‘‘Successful’’ treatment is deﬁned as
long-term viral suppression, while ‘‘unsuccessful’’ treatment
is viral outgrowth (treatment failure). A fraction of patients
fail treatment each year, from which point their progression
through the stages to AIDS is faster. Patients may also develop
resistance as a result of treatment failure or become super-
infected with ART-resistant virus. In the case of primary
resistance, there is also staged progression back to AIDS upon
treatment initiation, but for simplicity, there is no ‘‘initial’’
period.
Parameter values. The majority of parameter values were
selected after a review of literature and are presented in
Table 1 and Table S1. The baseline values were used for
model runs in Figures 2 and 3, and the ranges were used for
the uncertainty analyses employed in Figures 4 and 5. Table 1
illustrates the range of parameter values used for Latin
hypercube sampling (LHS) [17] and for the best- and worst-
case scenarios for ART, both used in Figures 4 and 5. LHS
parameters were varied independently of one another.
‘‘Best-’’ and ‘‘worst-case’’ scenarios in Table 1 refer to the
effectiveness of ART provision in terms of mortality and
Figure 1. Schematic Illustration of the Structure of the HIV Transmission Model
For clarity, stages of infection (primary infection, incubation, pre-AIDS, and AIDS) and death rates are not shown. ‘‘18 Res’’ denotes those with primary
(transmitted) resistance, while ‘‘28 Res’’ denotes those with secondary (acquired) resistance. ‘‘ART-Sens’’ denotes people infected with ART-sensitive
virus. Treatment withdrawal, used in some scenarios, is shown in grey.
DOI: 10.1371/journal.pmed.0030124.g001
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period and treatment failure for all ART recipients. This is to
reﬂect the success of the programme in promoting adher-
ence, ensuring adequate drug supplies, managing complica-
tions, and providing other medications and nutritional
supplements where necessary. A best-case scenario would
have low rates of treatment failure, because patient adher-
ence is high and drop-out low. A full listing of all model
parameters and additional reference sources is provided in
Table S1.
Reliable estimates for partner change rates and HIV
infectiousness are difﬁcult to obtain [18,19]. Parameter values
were chosen to represent the HIV epidemic in Malawi as
closely as possible, using data on HIV prevalence from
antenatal clinics in major urban areas [20]. Malawi was chosen
as an example of a country with a mature, high-prevalence
HIV epidemic and limited resources with which to provide
ART for all those in need. These values also reﬂect the
situation in resource-poor settings more generally. Partner
change rates, distributions of individuals between sexual
activity groups, and degree of assortative mixing between
these groups were parameterised by ﬁtting the model to the
prevalence data using the curve ﬁt function in Berkeley
Madonna, having seeded the population with ﬁve infected
individuals with primary infection in the highest sexual
activity class (we consider a hypothetical ART programme in
a population of one million). The partner change rate for
individuals in the highest-risk group is set very high, at 153
partners per year, while that of the lowest-risk group is just
0.23 partners per year, in order to mimic the timing and scale
of the Malawi epidemic as closely as possible, with a peak
prevalence of 27%. There are large differences in HIV
prevalence between major urban and non-urban areas in
Malawi [20]. We calibrated the model to urban prevalence, as
Table 1. Descriptions and Baseline Values of Some Key Model Parameters, with Sources
Parameter Type Parameter Description Value Sources
Biological parameters Duration of pre-AIDS stage 1 y [29–31]
Duration before death with AIDS (all infection categories) 9 mo [32,33]
Treatment parameters Fraction of treated patients with viral rebound developing
resistance at each treatment stage
40%; LHS range: 20%–60% [34–36]
Fraction of treated patients who drop out after each
treatment stage due to side effects
2%; LHS range: 1%–5% [35,36]
Fraction of AIDS patients initiating ART who drop out
due to side effects during the ‘‘initial’’ phase
5%, best-case scenario;
15%, worst-case scenario
[37,38]
Fraction of treated patients who suffer viral rebound at
each treatment stage
10%, best-case scenario;
30%, worst-case scenario
[31,39]
Fraction of AIDS patients initiating ART who develop
viral rebound or failure to suppress during the ‘‘initial’’ phase
30%, best-case scenario;
50%, worst-case scenario
[21,40]
Exit rate from ‘‘initial’’ phase for patients first starting ART 2 per year (average duration: 6 mo) [41,42]
Fraction of AIDS patients initiating ART who die during the
‘‘initial’’ phase
10%, best-case scenario;
20%, worst-case scenario
[22,43,44]
Baseline rate of withdrawal of failing therapy (primary or
secondary resistance or other viral rebound)
0 per year —
Rate of transfer to next treatment stage, successful viral suppression 1 per year (average duration
before progression to AIDS: 8 y)
[45]
Factor increase in rate of transfer to next treatment stage, patients
with viral rebound and/or resistance (duration before AIDS 80%
of that for patients with viral suppression)
1.25 [22,45]
Factor increase in rate of transfer to next treatment stage after
removal of ART (duration before AIDS 20% of that for patients with
viral suppression)
5 [46,47]
Relative transmission probability per partnership for patients with
viral suppression on ART, compared with untreated individuals
2%; LHS range: 1%–10% [41,42]
Relative transmission probability per partnership for patients with
viral rebound and/or resistance receiving ART, compared with
untreated individuals
75%; LHS range: 50%–100% [38,43]
Relative transmission probability per partnership for patients with
viral rebound and/or resistance and not on ART, compared with
untreated individuals
100% [43]
Probability that an untreated individual with secondary resistance
transmits resistant rather than sensitive virus
5%; LHS range: 0%–10% [48,49]
Probability that a treated individual with secondary resistance
transmits resistant rather than sensitive virus
30%; LHS range: 20%–40% [43]
Probability that an untreated individual with primary resistance
transmits resistant rather than sensitive virus during primary (acute) infection
100%; LHS range: 75%–100% [45,50]
Probability that an untreated individual with primary resistance
transmits resistant virus, all other stages of infection
5%; LHS range: 0%–10% [45,50]
Probability that a treated individual with primary resistance transmits
resistant virus rather than sensitive virus
100% Model assumption
DOI: 10.1371/journal.pmed.0030124.t001
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gradual roll-out to other regions. A graph comparing the
model simulation run using the parameters in Table 1 with
the antenatal clinic prevalence data from Malawi is shown in
Figure S1.
Life-years gained for each scenario were calculated by
integrating the total number alive and comparing with the
no-treatment scenario. Person-years of treatment were
calculated by integrating the total number on treatment.
Analyses of ART Effect
Effect of ART on different HIV epidemics. In order to
model different types of HIV epidemics, with different basic
reproductive numbers and thus scales, the partner change
rates across all activity groups were cut to one-third of their
original value, generating an epidemic with a peak prevalence
of 14.4%. ART was introduced in 2010 and 2040 to investigate
the impact by maturity of each epidemic, with unlimited
treatment of eligible individuals (details are provided in
Table 2). HIV patients are recruited into the ART programme
very quickly (an average of one month after qualifying for
treatment due to reaching the appropriate HIV infection
stage). This represents the most optimistic scenario, in which
all individuals qualifying for ART are screened, identiﬁed,
and treated virtually immediately, in order to investigate the
maximum impact of ART. Results are investigated with
baseline assumptions regarding behaviour change upon
initiating ART, as described above, compared with more
pessimistic assumptions, as described in Table 3.
Impact of ART—Levels of coverage. Using baseline values
for all parameters (Table 1) and for baseline changes in risk-
taking behaviour upon initiating ART, key outcome measures
were recorded for ART programme capacities ranging from
5,000 to 60,000 patients. Best- and worst-case scenarios as well
as scenarios in which AIDS patients only versus AIDS and pre-
AIDS patients qualiﬁed for treatment were calculated. ART
wasintroducedin2010withanuptakerateof12,whichequates
touptakeofARTanaverageofonemonthafterprogressingto
the eligible treatment stage, either AIDS or pre-AIDS.
Impact of ART—Treatment strategies. To represent the
availability or absence of CD4 count testing and viral load
monitoring, timing of treatment initiation, and withdrawal of
failing treatment, parameters were varied as described in
Table 4. The model assumes that without CD4 count or viral
load testing, only AIDS patients (deﬁned as those showing
ADCs) can be identiﬁed and treated (scenarios A and D; Table
4). A programme that offers CD4 count testing can treat
individuals at an earlier stage of immunologic decline, at the
pre-AIDS stage (scenarios B and C, E–G; Table 4). Where
drugs are rationed, we explored two possible approaches:
treatment in the order in which patients present to the clinic
(a ‘‘ﬁrst come, ﬁrst served’’ approach, scenario B; Table 4), or
preferential treatment of patients most likely to beneﬁt from
ART and least likely to suffer complications such as immune
Figure 2. Total Number of HIV Infections through Time for Various HIV Epidemics and under Different Assumptions regarding Behaviour Change of
Treated Patients
(A) and (B) illustrate a high prevalence, mature epidemic, similar to that of Malawi; (C) and (D) a smaller-scale epidemic (partner change rates one-third
of those for the Malawi simulation). (A) and (C) introduce ART in 2010, before equilibrium for (A) and early in the epidemic for (C); (B) and (D) introduce
ART in 2040, once equilibrium is reached for (B) and after the peak of the epidemic for (D). For each HIV epidemic scenario graph, two treatment options
and two behaviour change scenarios are illustrated: (1) treatment of AIDS patients only, baseline behaviour change assumptions (Table 3); (2) treatment
of AIDS patients only, pessimistic behaviour change assumptions (Table 3); (3) treatment of AIDS and pre-AIDS patients, baseline behaviour change
assumptions; (4) treatment of AIDS and pre-AIDS patients, pessimistic behaviour change assumptions.
DOI: 10.1371/journal.pmed.0030124.g002
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Antiretrovirals in Developing CountriesFigure 3. Total Number of HIV Infections Averted per Person-Year of Treatment for Various HIV Epidemics and under Different Assumptions regarding
Behaviour Change of Treated Patients
Scenarios as for Figure 2.
DOI: 10.1371/journal.pmed.0030124.g003
Figure 4. Effect of Programme Capacity
Outcome measures ten years after introduction of ART compared with no treatment, for various levels of coverage (ART programme capacities of 5,000
to 60,000) and for treating AIDS patients only or AIDS and pre-AIDS patients. Results are for the epidemic calibrated to Malawi prevalence data. Best-
and worst-case scenarios refer to optimistic or pessimistic outcomes of ART use, respectively (see Table 1). Shown are coverage level, defined as
proportion of individuals in need (AIDS and pre-AIDS patients) receiving ART (A); cumulative number of life-years gained over ten years, per person-year
of treatment (B); HIV infections averted per person year of treatment over ten years (C); and current number of ART-resistant infections ten years after
ART introduction (D). Results are the median values of the LHS sensitivity analysis; error bars represent the interquartile range.
DOI: 10.1371/journal.pmed.0030124.g004
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prognosis’’ approach, scenario C; Table 4).
Treatment failure in this case was deﬁned as viral rebound,
which can often precede immunologic treatment failure
(decline in CD4 count) and clinical progression by a consid-
erable period [15], with patients still able to respond well to
ART [21,22]. Scenario D investigates clinical management,
wherepatientshavingfailedARTareremovedfromtherapyan
average of three months after developing AIDS. In scenario E,
although CD4 testing would allow earlier detection of
immunologic treatment failure, it is still assumed that ART is
withdrawn only from those with AIDS, whereas the earlier
Figure 5. Description of Potential Treatment Strategies for ART Programmes in Resource-Limited Settings
Types of ART programme may vary by availability of laboratory tests (CD4 count and viral load testing) and approach to rationing (preferentially treating
those at different stages of infection and possibly withdrawing failing treatment). Different strategies are simulated by varying which populations
qualify for treatment, and withdrawal of therapy after viral rebound, immunologic, or clinical treatment failure. Outcome measures are ten years after
introduction of ART compared with no treatment. The seven scenarios, labelled A–G on the x-axes of the bar graphs, refer to different levels of use of
laboratory testing and prioritisation of different groups of patients (see Table 4). Best and worst cases refer to optimistic and pessimistic assumptions
regarding ART (see Table 1). Shown are cumulative life-years gained per person-year of treatment compared to no treatment (A); average duration on
ART per patient and cumulative number ever treated (B); HIV infections and deaths (all causes) averted per person-year of treatment compared to no
treatment (C); and proportion of all infections in the population that are ART-resistant at ten years after ART introduction (D). Results are the median
values of the LHS sensitivity analysis; error bars represent the interquartile range.
DOI: 10.1371/journal.pmed.0030124.g005
Table 2. Summary of Treatment Scenarios—Effect of ART on Various Epidemics: Changes in Size and Maturity of HIV Epidemic
Graph
a Partner Change Rate by Sexual Activity Class (per Year) Proportion in Each Activity Class (%) Year ART Introduced
1 2 341 2 3 4
A 152.8 13.6 0.5 0.2 0.1 26 59 15 2010
B 152.8 13.6 0.5 0.2 0.1 26 59 15 2040
C 50.9 4.5 0.2 0.1 0.1 26 59 15 2010
D 50.9 4.5 0.2 0.1 0.1 26 59 15 2040
Other parameters: All other parameters as in Table 1 using best-case scenario values with unlimited treatment coverage.
aGraphs A–D refer to those described in Figures 2 and 3: A, high-prevalence, mature epidemic with ART introduced in 2010 before epidemic equilibrium; B, high-prevalence, mature epidemic with ART introduced in 2040
once epidemic equilibrium is reached; C, smaller-scale epidemic with ART introduced in 2010 early in the epidemic; D, smaller-scale epidemic with ART introduced in 2040 after the peak of the epidemic.
DOI: 10.1371/journal.pmed.0030124.t002
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Scenario F involves withdrawal of ART at this detection stage,
when immunologic decline is identiﬁed. ART is withdrawn
frompatients one treatment stagebefore progressing toAIDS,
i.e., within a year of developing a new ADC.
Scenario G incorporates viral load testing and assumes the
extreme measure of withdrawing all ART at the earliest
deﬁnition of treatment failure, viral rebound, when patients
are still beneﬁting from treatment. Viral load testing is
assumed to identify treatment failure and facilitate with-
drawal of individuals from therapy less than one year after
treatment failure.
Results
Effect of ART on Various HIV Epidemics
The scenarios in Figures 2 and 3 illustrate the various long-
term impacts that ART may have on HIV prevalence when its
availability is not limited. The impact of widespread ART on
the HIV epidemic (Figure 2) and cumulative HIV infections
averted per person-year of treatment (Figure 3) is illustrated.
All scenarios have high treatment uptake rates, requiring a
rigorous screening programme in order to identify all
patients eligible for ART, and the best-case scenarios are
used. Therefore this result represents the best possible
outcome of ART introduction.
The impacts of treating AIDS patients and pre-AIDS
patients differed, partly because, in these unlimited-treat-
ment scenarios, the numbers receiving ART differed sub-
stantially. Treating solely AIDS patients increased prevalence
for all modelled epidemics by increasing life expectancy,
while additionally treating pre-AIDS patients initially coun-
teracted this increase to some extent by averting more
infections (Figure 3). Changing the assumptions regarding
behaviour change upon initiation of ART (see Table 3 for
details) had little effect when ART eligibility was limited to
AIDS patients. In contrast, the ‘‘pessimistic’’ assumption of an
absence of behaviour change for treated pre-AIDS patients
(scenario 4; Table 3) substantially increased prevalence for all
scenarios, especially for the epidemic with the lower partner
change rates and R0 (Figure 2). The model suggests that the
most ‘‘optimistic’’ impact that ART may have on an HIV
Table 3. Summary of Treatment Scenarios—Effect of ART on Various Epidemics: Changes in ART Patients’ Risk-Taking Behaviours
Scenario Treatment Uptake
Rates (per Year)
Risk-Taking
Behaviour Assumptions
AIDS Pre-AIDS AIDS Pre-AIDS
1 12 0 Baseline—Patients stay in (lowest) sexual
activity group 4 or move to group 3
No change (not treated)
2 12 0 Pessimistic—Patients stay in (lowest) sexual
activity group 4 or move to groups 2 and 3
No change (not treated)
3 12 12 Baseline—Patients stay in (lowest) sexual
activity group 4 or move to group 3
Baseline—Patients move to the next lowest
(less active) sexual activity group
4 12 12 Baseline—Patients stay in (lowest) sexual
activity group 4 or move to group 3
Pessimistic—No change in sexual activity group
5 0 0 No change No change
Other parameters: All other parameters as in Table 1 using best case scenario values with unlimited treatment coverage.
DOI: 10.1371/journal.pmed.0030124.t003
Table 4. Summary of Treatment Scenarios—Availability of Laboratory Facilities
Scenario Entry Criterion ART Uptake Rates (per Year) Withdrawal of ART
a
AIDS Pre-AIDS
A Clinical management or ‘‘most in need’’ AIDS only 12 0 No withdrawal
B CD4 testing and ‘‘first come, first served’’ AIDS and pre-AIDS 12 12 No withdrawal
C CD4 testing and ‘‘best prognosis’’ Pre-Aids only 0 12 No withdrawal
D Treatment withdrawal, clinical management AIDS only 12 0 Rate of ART withdrawal upon
progressing to AIDS ¼ 4 (per year)
E CD4 testing and ‘‘first come, first served’’
with treatment withdrawal
AIDS and pre-AIDS 12 12 Rate of ART withdrawal upon
progressing to AIDS ¼ 4 (per year)
F Treatment withdrawal, CD4 count testing AIDS and pre-AIDS 12 12 Patients removed from ART one
treatment stage before progressing
to AIDS for all treated compartments
G Treatment withdrawal, CD4 count and
viral load testing
AIDS and pre-AIDS 12 12 Patients removed from ART one treatment
stage after developing viral rebound
aWithdrawal as a result of treatment failure (defined as viral rebound or failed viral suppression, with or without drug resistance). Treatment introduced at 2010. Other parameters: maximum number on treatment¼5,000.
Best- and worst-case scenarios refer to optimistic and pessimistic selection of parameters regarding treatment failure rates (Table 1). Baseline assumptions regarding behaviour change upon initiating ART are assumed.
DOI: 10.1371/journal.pmed.0030124.t004
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in number of infections; this scenario would require treat-
ment of all AIDS and pre-AIDS patients, accompanied by
signiﬁcant change in risk-taking behaviour, and an epidemic
with an intrinsically low R0 (Figure 2C and 2D). Figure 3
suggests that, although treating pre-AIDS patients may
prevent infections in the short term, over the long term the
net gain is considerably reduced. This is not due to outgrowth
of ART-resistant viruses; the constraint that wild-type is more
transmissible than the resistant phenotype prevents substan-
tial primary resistance under this choice of parameters.
Rather, the immediate effect of decreased risk-taking
behaviour among treated patients was negated by their
increased life expectancy.
Impact of ART—Levels of Coverage
The effect when there are no constraints on the availability
of ART drugs was compared with a limited number being
treated at any one time, to reﬂect resource constraints
(Figure 4). The implication for treatment coverage, in terms
of proportion of individuals in need (AIDS and pre-AIDS
patients) receiving ART for each programme capacity, is
shown in Figure 4A.
Because of the limited effect of treatment on transmission,
the beneﬁts of ART to the community per person-year of
treatment did not vary substantially with the capacity of a
programme, as measured by life-years gained (Figure 4B).
Each additional person treated produced the same beneﬁt in
terms of life-years gained and transmission and morbidity
reduced—for a mature epidemic, there would be no herd
effect producing a non-linear pattern of beneﬁt of increasing
access to ART in the short term. Paradoxically, treating both
AIDS and pre-AIDS patients saved fewer life-years per person
year of treatment than an AIDS-only approach, despite the
fact that treating pre-AIDS averted more infections over this
period (Figures 3A and 4C). The beneﬁts of delaying
imminent AIDS deaths were demonstrated immediately,
while the prevention of future deaths by preventing infection
was revealed more slowly. The number of life-years saved per
person-year of treatment for pre-AIDS and AIDS treatment
overtook that for AIDS-only treatment by 2029 when the
model was run with a capacity of 30,000 ART patients and
best-case scenario parameters (Figure S2).
A greater degree of coverage led to a greater degree of viral
resistance evolution and potential spread (Figure 4D).
Furthermore, the greater the coverage of a poorly run
programme, where resistance evolution is frequent, the
greater the opportunity for relatively ﬁt ART-resistant
mutants to evolve, which may compromise the entire
programme in that area and possibly others.
Impact of ART—Treatment Strategies
Scenarios that may potentially be adopted by ART
programmes in resource-constrained settings are described
in Table 4 and Methods (section titled ‘‘Impact of ART—
Treatment Strategies’’), and relate not only to the availability
of laboratory facilities but also to the priorities for treatment
assigned by public health ofﬁcials. We assumed that initiating
treatment before extensive destruction of the cellular
immune system, at pre-AIDS rather than AIDS, leads to less
risk of mortality, treatment failure, and dropout due to drug
intolerance. We also assumed that treatment failure leads to a
decrease in treatment effectiveness, but that ART still has a
substantial beneﬁcial effect in the ‘‘failed patient’’ (see Table
1).
Figure 5A again shows that ten years after treatment
introduction, the beneﬁts of averting new infections by
treating pre-AIDS patients are not evident, so treating only
AIDS patients appears to confer more beneﬁt in terms of life-
years gained (scenario A versus scenario C). Figure 5B shows
that without treatment withdrawal, pre-AIDS patients re-
mained on ART substantially longer than did AIDS patients,
because they have a better prognosis (lower mortality and
likelihood of treatment failure). The inﬂuence of rates of
treatment failure on duration of ART is shown by the large
differences between best- and worst-case scenarios. Treat-
ment withdrawal signiﬁcantly decreased the average duration
on ART, by over a year in some scenarios. Figure 5C shows
that the earlier that individuals were placed on ART, the
more infections were averted under these assumptions
regarding behaviour change. Figure 5D shows population-
level resistance prevalence, which appears relatively low, but
was the result of relatively small coverage of the population
(approximately 20% of all those in need at 2020).
For treatment withdrawal based on clinical management,
there was little impact in terms of infections averted and
resistance emergence (scenarios A versus D, and B versus E;
Figure 5C and 5D). ART withdrawal was just a few months
before death from AIDS, but in the context of rationing, this
would free up treatment for others. Therefore, both life-years
gained per person-year of treatment and the number of
individuals that can be reached with ART increased slightly,
because resources would be directed in a more ‘‘efﬁcient’’
way (Figure 5). However, the difference in life-years gained
for all scenarios was small; all patients must receive ART
continuously to beneﬁt, so this is not surprising. Assumptions
regarding treatment withdrawal for scenario G (Figure 5)
meant that ART was withdrawn from all patients after
treatment failure but before emergence of drug resistance;
this is unrealistic, but it illustrates the maximum impact that
such a policy could have (Figure 5D). A substantial effect on
preventing resistance is observed only for scenario G, with
ART withdrawal after viral rebound. Viral rebound can occur
shortly after initiating therapy, and potentially years before
immunologic decline, while patients are free from symptoms,
so risk-taking behaviour could be relatively high and thus
there is considerable opportunity for transmission of
resistant strains. If withdrawal is only after CD4 counts begin
to drop, the chance of resistance transmission is substantially
less. The impact on HIV transmission and life-years gained
remained minimal (Figure 5C), and patients’ duration on
ART (a measure of life expectancy) was substantially reduced,
although total numbers beneﬁting from therapy increased
(Figure 5B).
Discussion
We have modelled the impact of ART on various types of
HIV epidemics in resource-poor settings more realistically
than hitherto, to investigate how the speciﬁc details of ART
programme implementation might affect epidemiological
and clinical impact. According to our modelling results,
HIV epidemics in sub-Saharan Africa are not amenable to
control through treatment, regardless of the extent of ART
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the absence of substantial behaviour change of treated
patients through effective counselling, prevalence is likely
to increase. Different coverage levels for ART would not
affect beneﬁts such as life-years gained per person-year of
treatment because of the limited effect of treatment on
transmission, but increasing coverage does increase the
emergence and spread of drug resistance. Scenarios inves-
tigating withdrawal of failing treatment increased the
numbers who could beneﬁt from AIDS, but effectiveness
per person was compromised. Only withdrawal at a very early
stage of treatment failure, soon after viral rebound, would
have a substantial impact on drug resistance emergence
(Figure 5D), because the majority of transmission of resistant
HIV strains would occur before immunologic treatment
failure. While our model assumes conservative estimates for
the ﬁtness of resistant strains, substantial viral replication
under continued treatment pressure could promote gener-
ation of even ﬁtter strains, increasing the frequency of
resistance transmission events.
While our model incorporated some behaviour change
upon initiating ART, it did not consider the complex effects
of voluntary counselling and testing on risk-taking behaviour.
Both uptake of testing and risk-taking behaviour may vary
substantially by scale of coverage and performance of ART
programmes, and their impact is likely to have a large effect
on prevalence. The model results suggest similar levels of
beneﬁt per person-year of treatment, regardless of the scale
of ART provision, but in reality, scaling up programmes is
likely to compromise quality, meaning higher dropout rates
and mortality and treatment failure, negating the beneﬁcial
impacts of ART and increasing the rate of drug resistance
emergence.
CD4 count testing allows the identiﬁcation of pre-AIDS
patients. Additionally, the implementation of laboratory
facilities for viral load monitoring allows the identiﬁcation
of treatment failure earlier, increasing the sustainability of
the programme, either by allowing switching to a salvage
regimen, or perhaps (in the absence of alternative treatments)
by halting therapy and giving the drugs to another patient
whose prognosis is better, as is investigated here. The beneﬁts
of viral load testing will increase with higher levels of
resistance in the population. The model does not incorporate
background drug resistance levels due to uses of ART outside
the modelled programme, but levels of resistance are likely to
be higher in many areas due to prevention of mother-to-child
transmission [23] and sporadic ART use [24], and because
some programmes have used only double or single therapy
[25,26]. For example, in the UNAIDS/Uganda Ministry of
Health Drug Access Initiative pilot project, only 64% of
patients were ART drug-naı ¨ve before enrolling in the
initiative [26].
Withdrawal of failing treatment, where this is deﬁned as
viral rebound or immunologic failure, when the patient
would still beneﬁt from continuing ART, is unlikely to be
acceptable to any ethics committee or government. However,
the exploration of this strategy through modelling has shown
the beneﬁts in terms of increasing access to (albeit less
effective) treatment to more individuals, and for withdrawal
upon viral rebound, slowing the emergence of drug resist-
ance. While the net health beneﬁts in terms of life-years
gained would be similar for each strategy, in a wider context,
factors such as delaying orphanhood by even a short time for
many patients’ children, or by a longer time for fewer, make
this comparison difﬁcult to evaluate.
Results from this model suggest that counselling of patients
to promote safe sexual practices is essential, and must aim to
effect long-term change and prevent behavioural disinhibi-
tion (increase in risk-taking behaviour in response to
perceptions of safety conferred by the use of ART), not only
for ART patients, but for all individuals. Withdrawal of
treatment at a potentially acceptable stage, that is, after
immunologic deterioration when ART is no longer of beneﬁt,
would not have a substantial effect on containing resistance
emergence, but would increase the number able to beneﬁt
from treatment where its availability is limited. As the pace of
ART roll-out across southern Africa quickens, difﬁcult
decisions regarding the allocation of ﬁnite resources will
have to be made. Mathematical models are increasingly being
employed to explore optimal strategies for allocation of these
funds [27,28]. Analysing the implications of different treat-
ment strategies, using data from early programmes coupled
with the types of modelling methods presented here, is
needed to give AIDS treatment and prevention programmes
the best possible chance of success.
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Figure S1. Comparison of Modelled Epidemic with Prevalence Data
Comparison of the projected epidemic using baseline parameter
values, with UNAIDS prevalence estimates from antenatal clinics in
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Treatment Strategies
Model run with treatment capacity of 30,000 and best-case scenario
parameters.
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Protocol S1. Model Description
Detailed description of the model, including transmission equations
and a full list of adopted parameter values.
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Table S1. Descriptions and Adopted Values of All Model Parameters
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Antiretrovirals in Developing CountriesPatient Summary
Background. Access to antiretroviral therapy (ART) is slowly increasing
in resource-poor countries. Strategies for how to achieve the greatest
health benefits with what will remain, at least in the near future, limited
resources are necessary and being developed. How to distribute a
limited amount of life-saving drugs in the face of a devastating
pandemic—in other words, how to decide who will not get treat-
ment—is a very difficult ethical question. Those who need to solve it
must learn as much as possible from the experiences of others. In
addition, theoretical predictions of the outcomes under different
scenarios can help. To this end, public health scientists are using
mathematical modelling of different scenarios of testing, treatment, and
counselling. For the modelling data to be useful, they must be based as
much as possible on realistic assumptions.
Why Was This Study Done? Sexual transmission of HIV is more likely if
the HIV-positive partner has a higher viral load. Because ART not only
slows AIDS progression but also reduces viral load in infected individuals,
the drugs therefore not only improve the health and prolong the life of
those who take the drugs but also make it less likely that they infect
others. As a consequence, ART has been discussed not only as a
treatment but also as a prevention tool in its own right. Mathematical
modelling supports the notion that ART can reduce transmission rates, as
long as the people receiving treatment do not change their sexual
behaviour towards riskier sex (unprotected intercourse, more partners,
etc.). So far, modelling the prevention effects has been based on
experiences in the US and Australia, where most HIV-infected individuals
get access to drugs during the early stages of infection, as soon as their
CD4 counts drop (this is unlikely to be the case in resource-poor settings
where many patients are diagnosed and treated only when they
experience AIDS symptoms). These researchers used more relevant
parameters to model the effects of ART on improving the health of those
treated and on HIV prevalence, i.e., the rate of new infections.
What Did the Researchers Do and Find? They used a model to predict
and compare the impacts of alternative strategies. Some of the strategies
included the provision of diagnostic laboratories that could routinely
measure CD4 counts and viral loads of HIV-infected individuals. Only if
this is done could people be treated before they develop overt
symptoms. They also took into account different ways that people
might change their sexual behaviour if they get treatment (which might
make them feel physically better and more likely to be sexually active)
and counselling (which will hopefully increase safe sex practices). They
found that providing ART to all individuals with AIDS symptoms (i.e.,
those at the late stages of the disease) was likely to increase the
prevalence of HIV infection, as these people live longer and become
sexually active again. If ART is also provided to people during the earlier
stages of infection, the outcome on HIV prevalence depends on the
behaviour of these individuals. If ART was more widely available, the risk
of the emergence of drug-resistant strains of the virus increased.
What Does This Mean? These results suggest that provision of ART to
symptomatic AIDS patients and/or those at the earlier stages of the
disease is not likely to prevent many new infections. It could even
increase transmission of the virus as patients live longer and are
healthier. Counselling patients and the rest of society to promote safe
sex practices must therefore be an essential part of any strategy if it is to
contain and reverse the AIDS epidemic. The model presented here can
support health policy makers in resource-poor settings in their difficult
task of allocating limited amounts of antiretroviral drugs for the greatest
benefit of their populations.
Where Can I Find More Information Online? WHO pages on HIV/AIDS:
http://www.who.int/hiv/en
Report from a Consultation on Anti-Retroviral Therapy for HIV
Prevention:
http://www.nih.gov/od/oar/public/pubs/art_12_00.htm
Report from a Consultation on Studies of HIV Disease in Developing
Countries:
http://www.nih.gov/od/oar/public/pubs/hivdeveloping.htm
Joint United Nations Programme on HIV/AIDS, World Health Organ-
ization. AIDS epidemic update 2004:
http://www.unaids.org/wad2004/report.html
Global HIV Prevention Working Group report, HIV Prevention in the Era
of Expanded Treatment Access:
http://www.gatesfoundation.org/nr/downloads/globalhealth/aids/
PWG2004Report.pdf
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